2. Molecular Medicine Unit. Department of Medicine. University of Salamanca Spain.
3. Department of Medicine, Division of Endocrinology and Metabolism, University of California-San Diego, La Jolla, California, USA.
4. Internal Medicine, Hospital de Ponferrada.
5. School of Medicine, University of California-San Diego, La Jolla, California, USA.
6. Networked Biomedical Research Center and Digestive Diseases – CIBERehd, Barcelona, Spain.
7. Institute for Medical Research of Salamanca (IBSAL), University of Salamanca-SACYL-CSIC, Spain.
8. Institute of Molecular and Cellular Biology of Cancer, University of Salamanca-CSIC, Spain.
Type 2 diabetes (T2D) is a disease whose occurrence is increasing prevalent in westernized civilizations and is responsible for the proliferation in the morbidity and total mortality of patients with cardiovascular diseases, worldwide. However, the complexity in the treatment and prevention of T2D arises from the intricacy of the many physical and biological factors involved in its etiology. Impaired pathways for insulin signaling have been implicated as one the many factors in the development of T2D Individual peroxisome proliferator-activated receptors (PPARs) have previously exhibited associations with alterations of lipid profiles, fat tissue and T2D and displayed complications derived from high levels of glucose. However, PPARgamma has not yet been associated with the development or developmental pathways of T2D. We performed an observational study a Spanish cohort in order to better understand the association between the SNP PPARgamma polymorphism Pro12Ala in our patients and the incidence of T2D and other cardiovascular complications. We study did not find a statistically significant relationship between the Pro12Ala and T2D development in our cohort, future observations will help us to know the association with vascular disease in patients with T2D.
Keywords: Diabetes type 2, PPARγ, polymorphism pro12Ala, spanish cohort